Title: Tdap Recommended for all Patients 65 Years and Older
题目：破伤风-白喉-百日咳疫苗（Tdap）可用于65岁以上的病人
Author 作者: Bryan Hayes

The two available Tetanus/reduced diphtheria toxoid/acellular pertussis (Tdap) vaccine products in the U.S. are Boostrix and Adacel. Neither were originally approved in older adults age 65 and older. Boostrix received FDA-approval for use in this age group in July 2011, but Adacel never has.
在美国，破伤风-白喉-百日咳疫苗（Tdap）有两种剂型，Boostrix （白喉、破伤风和高纯度无细胞百日咳抗原的加强型疫苗）和Adacel （抗白喉、百日咳、脊髓灰质炎和破伤风感染的加强型疫苗）。没有一个在开始时用于65岁以上的病人。但在2011年7月，美国食品药物管理局（FDA）批准了Boostrix在这一年龄段病人中的应用。Adacel还没有。
However, in June 2012 ACIP issued new guidance recommending Tdap for all adults age 65 years and older. 
但是，在2012年6月，美国免疫疫苗实践顾问委员会（ACIP）发表了一个新的指南，建议两个Tdap疫苗都可用于65岁以上的病人。
"When feasible, Boostrix should be used for adults aged 65 years and older; however, ACIP concluded that either vaccine administered to a person 65 years or older is immunogenic and would provide protection. A dose of either vaccine may be considered valid."
“如有可能，对65岁以上的病人要用Boostrix。但是，ACIP规定在65岁以上病人应用任何一个疫苗都会产生免疫效应，起到保护作用。一个计量的任何一个疫苗都可以认为是有效的。“
Bottom line: Regardless of which Tdap product is stocked at your institution, both are considered safe to use in adults 65 years and older.
要点：根据你们医疗机构的药房Tdap疫苗产品储备情况，两个疫苗都可以安全的用于65岁以上的病人。
 

References 参考文献
Centers for Disease Control and Prevention (CDC), “Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Adults Aged 65 Years and Older - Advisory Committee on Immunization Practices (ACIP)," MMWR Morb Mortal Wkly Rep, 2012, 61(25):468-70. [PMID 22739778]